Association of common variation in the PPARA gene with incident myocardial infarction in individuals with type 2 diabetes: A Go-DARTS study

Nuclear Receptor

Volumn 3, Issue , 2005, Pages

  Doney, Alex S F ^a   Fischer, Bettina ^a   Lee, Simon ^a   Morris, Andrew D ^a   Leese, Graham P ^a   Palmer, Colin N A ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; GLYCINE; LEUCINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; VALINE;

ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SIMILARITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEALTH CARE ORGANIZATION; HEART INFARCTION; HUMAN; INCIDENCE; INDIVIDUALITY; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONBIOLOGICAL MODEL; PROSPECTIVE STUDY; QUALITATIVE ANALYSIS; SEX DIFFERENCE; UNITED KINGDOM;

EID: 28844489398     PISSN: 14781336     EISSN: 14781336     Source Type: Journal    
DOI: 10.1186/1478-1336-3-4     Document Type: Article

References (29)

1. McGarry JD: Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002, 51(1):7-18.
2. Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W: Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997, 11(6):779-791.
3. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta. and -gamma in the adult rat. Endocrinology 1996,137(1):354-366.
4. Marx N, Duez H, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004, 94(9):1168-1178.
5. Vosper H, Khoudoli GA, Graham TL, Palmer CN: Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis. Pharmacol Ther 2002, 95(1):47-62.
6. Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE: Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia 2000, 43(5):673-680.
7. Sapone A, Peters JM, Sakai S, Tomita S, Papiha SS, Dai R, Friedman FK, Gonzalez FJ: The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics 2000, 10(4):321-333.
8. Vohl MC, Lepage P, Gaudet D, Brewer CG, Betard C, Perron P, Houde G, Cellier C, Faith JM, Despres JP, Morgan K, Hudson TJ: Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res 2000, 41(6):945-952.
9. Jamshidi Y, Montgomery HE, Hense HW, Myerson SG, Torra IP, Staels B, World MJ, Doering A, Erdmann J, Hengstenberg C, Humphries SE, Schunkert H, Flavell DM: Peroxisome proliferator - activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension. Circulation 2002, 105(8):950-955.
10. Tai ES, Demissie S, Cupples LA, Corella D, Wilson PW, Schaefer EJ, Ordovas JM: Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2002, 22(5):805-810.
11. Flavell DM, Jamshidi Y, Hawe E, Pineda Torra I, Taskinen MR, Frick MH, Nieminen MS, Kesaniemi YA, Pasternack A, Staels B, Miller G, Humphries SE, Talmud PJ, Syvanne M: Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 2002, 105(12):1440-1445.
12. Flavell DM, Ireland H, Stephens JW, Hawe E, Acharya J, Mather H, Hurel SJ, Humphries SE: Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes. Diabetes 2005, 54(2):582-586.
13. Robins SJ: Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy? Curr Opin Lipidol 2003, 14(6):575-583.
14. Doney AS, Fischer B, Leese G, Morris AD, Palmer CN: Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study. Arterioscler Thromb Vasc Biol 2004, 24(12):2403-2407.
15. Doney AS, Fischer B, Cecil JE, Boylan K, McGuigan FE, Ralston SH, Morris AD, Palmer CN: Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia 2004, 47(3):555-558.
16. Morris AD, Boyle DI, MacAlpine R, Emslie-Smith A, Jung RT, Newton RW, MacDonald TM: The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration.[see comment]. BMJ 1997, 315(7107):524-528.
17. Lacquemant C, Lepretre F, Pineda Torra I, Manraj M, Charpentier G, Ruiz J, Staels B, Froguel P: Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease. Diabetes & Metabolism 2000, 26(5):393-401.
18. Jamshidi Y, Flavell DM, Hawe E, MacCallum PK, Meade TW, Humphries SE: Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial. Atherosclerosis 2002, 163(1):183-192.
19. Gouni-Berthold I, Giannakidou E, Muller-Wieland D, Faust M, Kotzka J, Berthold HK, Krone W: Association between the PPARalpha L162V polymorphism, plasma lipoprotein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in nondiabetic controls. American Heart Journal 2004, 147(6):1117-1124.
20. Skogsberg J, Kannisto K, Cassel TN, Hamsten A, Eriksson P, Ehrenborg E: Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men. Arteriosclerosis, Thrombosis & Vascular Biology 2003, 23(4):637-643.
21. Paradis AM, Fontaine-Bisson B, Bosse Y, Robitaille J, Lemieux S, Jacques H, Lamarche B, Tchernof A, Couture P, Vohl MC: The peroxisome proliferator-activated receptor alpha Leu162Val polymorphism influences the metabolic response to a dietary intervention altering fatty acid proportions in healthy men. American Journal of Clinical Nutrition 2005, 81(2):523-530.
22. Tai ES, Corella D, Demissie S, Cupples LA, Coltell O, Schaefer EJ, Tucker KL, Ordovas JM: Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. J Nutr 2005, 135(3):397-403.
23. Bosse Y, Pascot A, Dumont M, Brochu M, Prud'homme D, Bergeron J, Despres JP, Vohl MC: Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil. Genetics in Medicine 2002, 4(4):311-315.
24. Brisson D, Ledoux K, Bosse Y, St-Pierre J, Julien P, Perron P, Hudson TJ, Vohl MC, Gaudet D: Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics 2002, 12(4):313-320.
25. Foucher C, Rattier S, Flavell DM, Talmud PJ, Humphries SE, Kastelein JJ, Ayyobi A, Pimstone S, Frohlich J, Ansquer JC, Steiner G, investigators D: Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. Pharmacogenetics 2004, 14(12):823-829.
26. Kroymann J, Mitchell-Olds T: Epistasis and balanced polymorphism influencing complex trait variation. Nature 2005, 435(7038):95-98.
27. Evans JM, Wang J, Morris AD: Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies.[erratum appears in BMJ 2002 Jun 8;324(7350):1357]. BMJ 2002, 324(7343):939-942.
28. Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL: A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm. Ann Hum Genet 2004, 68(Pt 2):165-177.
29. Tregouet DA, Tiret L: Cox proportional hazards survival regression in haplotype-based association analysis using the Stochastic-EM algorithm. Eur J Hum Genet 2004, 12(11):971-974.